Forecast
The analysts' average price target is €33.38 (+6.31%). The median is €35.54 (+13.18%).
| Buy |
17 |
| Hold |
7 |
| Sell |
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Acadia Healthcare sees $200m EBITDA potential from 3,000 new beds
At the Jefferies conference Acadia Healthcare said demand for behavioral health services remains strong while the company works to convert the 3,000 beds opened since 2023 into stable earnings and cash flow. Management cited receivable write-offs, claim denials and start-up losses as near-term headwinds but is confident it can realize about $200 million of incremental EBITDA through accreditations, contract negotiations with payers and higher occupancy. CEO Debbie Osteen promised a “return to basics” and tight execution; one new facility already reached break-even in about a year. The company reports stabilized daily revenues, improved employee retention and expects pressure from receivable write-offs to ease over the course of the year. » More on de.investing.com
Acadia Healthcare: KeyBanc raises price target to 40 USD after rising occupancy rates
KeyBanc has raised its price target for Acadia Healthcare to 40 USD, driving the stock on high volume. The reason is growing occupancy rates in the psychiatric clinics and ongoing capacity expansions. Analysts see further substantial upside for the U.S. clinic operator against the backdrop of the mental-health megatrend. » More on finanzen.net
Acadia Healthcare hits new 52-week high at $32.82
Acadia Healthcare’s stock rose to a 52-week high of $32.82, gaining 43.92% over the past year. Over the past six months the price increased by 165%, and year-to-date by 123%. Analyst updates, including upgrades from Jefferies and affirmed overweight ratings from KeyBanc, highlight operational improvements under new management and further growth potential. An InvestingPro analysis currently rates the stock as undervalued and sees additional upside potential. » More on de.investing.com
Acadia Healthcare sees analyst upgrades but faces bad-debt headwinds
Analysts raised ratings and price targets after Acadia Healthcare reported a strong Q1 and modestly increased 2026 earnings and EBITDA guidance, with Raymond James upgrading to Strong Buy and lifting its target to $39. Cantor Fitzgerald raised its target to $30 but kept a Neutral rating, citing escalating bad debt and claim denials that offset some operational improvements. Acadia is pursuing $200 million in recoveries from underperforming locations while maintaining modest growth, leaving short-term outlooks uncertain despite positive core performance. » More on finance.yahoo.com
Acadia Healthcare gets lifted price targets from RBC and Raymond James after Q1 beat
RBC Capital raised its price target on Acadia Healthcare to $31 from $28 and reiterated an Outperform rating after the company beat fiscal Q1 expectations. Raymond James upgraded the stock to Strong Buy, boosting its target to $39 from $25 and modestly raising its 2026 EBITDA and earnings outlook. Raymond James said Acadia can harvest about $200M from underperforming facilities and expects modest underlying growth driving higher estimates and a richer multiple. » More on finance.yahoo.com
Historical dividends Dividends
All dividend metrics All metricsIn 2022, Acadia Healthcare has already paid €0.72 in dividends. The last payout was in February 2022.
Financials
In the last quarter, Acadia Healthcare had revenue of €790.42M and net profit of €30.45M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 790.42M | 8.93% |
| Gross profit | 152.5M | 78.21% |
| Net profit | 30.45M | 1.43% |
| EBITDA | 129.67M | 22.65% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.93B |
Number of shares | 92.97M |
52-week high/low | €36.18 - €10.42 |
| Dividends | No |
Beta | 0.63 |
P/E ratio | -2.77 |
PEG ratio | 0.00 |
P/B ratio | 1.55 |
P/S ratio | 0.94 |
Company profile
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico. The company operates acute inpatient psychiatric facilities, which cares to stabilize patients that are either threat to themselves or 24-hour observation, daily intervention, and monitoring by psychiatrists; and specialty treatment facilities, including residential recovery and eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders. It also provides residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs; and offer therapeutic placement for children and adolescents with emotional disorders. As of February 28, 2022, it operated a network of 228 behavioral healthcare facilities with approximately 10,500 beds. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
| Name | Acadia Healthcare |
| CEO | Debra K. Osteen |
| Headquarters | Franklin,
tn USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 12/07/2015 |
| Employees | 22,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ACHC |
Frankfurt | 7RA.F |
Düsseldorf | 7RA.DU |
München | 7RA.MU |